"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
| Descriptor ID |
D019808
|
| MeSH Number(s) |
D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
|
| Concept/Terms |
Losartan- Losartan
- 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
Losartan Potassium- Losartan Potassium
- Potassium, Losartan
- Losartan Monopotassium Salt
- Monopotassium Salt, Losartan
- Salt, Losartan Monopotassium
|
Below are MeSH descriptors whose meaning is more general than "Losartan".
Below are MeSH descriptors whose meaning is more specific than "Losartan".
This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 2 | 3 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Losartan" by people in Profiles.
-
Nu?ez RE, Javadov S, Escobales N. Critical role of angiotensin II type 2 receptors in the control of mitochondrial and cardiac function in angiotensin II-preconditioned rat hearts. Pflugers Arch. 2018 09; 470(9):1391-1403.
-
Gerena Y, Lozada JG, Collazo BJ, M?ndez-?lvarez J, M?ndez-Estrada J, De Mello WC. Losartan counteracts the effects of cardiomyocyte swelling on glucose uptake and insulin receptor substrate-1 levels. Peptides. 2017 Oct; 96:38-43.
-
Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, George A, Raj AB, Nero AC, Terrell CE, McCord L, Lane A, Ackerman HC, Yang Y, Niss O, Taylor MD, Devarajan P, Malik P. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. Am J Hematol. 2017 Sep; 92(9):E520-E528.
-
Javadov S, Escobales N. The Role of SIRT3 in Mediating Cardioprotective Effects of RAS Inhibition on Cardiac Ischemia-Reperfusion. J Pharm Pharm Sci. 2015; 18(3):547-50.
-
Hern?ndez JS, Barreto-Torres G, Kuznetsov AV, Khuchua Z, Javadov S. Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. J Cell Mol Med. 2014 Apr; 18(4):709-20.
-
De Mello WC. Intracrine action of angiotensin II in the intact ventricle of the failing heart: angiotensin II changes cardiac excitability from within. Mol Cell Biochem. 2011 Dec; 358(1-2):309-15.
-
Xu X, Zhao W, Wan W, Ji LL, Powers AS, Erikson JM, Zhang JQ. Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats. Exp Physiol. 2010 Oct; 95(10):1008-15.
-
De Mello WC, Gerena Y. Prolonged exposure of cardiac cells to renin plus angiotensinogen reduces intracellular renin in the failing heart. On the role of angiotensin II-AT1 complex internalization. Regul Pept. 2009 Jun 05; 155(1-3):139-44.
-
Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
-
Crespo MJ, Cruz N, Altieri PI, Escobales N. Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster. J Cardiovasc Pharmacol Ther. 2008 Sep; 13(3):199-206.